These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8232870)

  • 21. Clinical experience with gadodiamide injection in magnetic resonance imaging of the central nervous system.
    Andrew E; Svaland M; Lundby B; Hugo F; LaFrance N
    Invest Radiol; 1994 Jun; 29 Suppl 2():S186-8. PubMed ID: 7928225
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of the magnetic resonance contrast agent gadodiamide in the central nervous system. Results of a multicenter trial.
    Sze G; Brant-Zawadzki M; McNamara MT; Haughton VM; Kumar AJ; Maravilla KR; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC
    Invest Radiol; 1993 Mar; 28 Suppl 1():S49-55. PubMed ID: 8486504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI of spontaneous spinal cord infarction: serial changes in gadolinium-DTPA enhancement.
    Hirono H; Yamadori A; Komiyama M; Yakura H; Yasui T
    Neuroradiology; 1992; 34(2):95-7. PubMed ID: 1603320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The contrast enhancement of brain and spinal cord tumors using Gd-DTPA in magnetic resonance tomography with an extra-low magnetic-field intensity].
    Kornienko VN; Pronin IN; Turkin AM; Fadeeva LM
    Zh Vopr Neirokhir Im N N Burdenko; 1993; (4):13-7. PubMed ID: 8296501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection.
    Van Wagoner M; O'Toole M; Quay SC
    Invest Radiol; 1990 Sep; 25 Suppl 1():S39-41. PubMed ID: 2283251
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety of gadodiamide injection in two different age groups.
    Högström B; Kristoffersen DT; Lundby B; Svaland MG
    J Magn Reson Imaging; 1996; 6(1):255-7. PubMed ID: 8851438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI diagnosis of intramedullary metastases from extra-CNS tumors.
    Crasto S; Duca S; Davini O; Rizzo L; Pavanello IG; Avataneo T; Cirillo S; Regge D; Soffietti R
    Eur Radiol; 1997; 7(5):732-6. PubMed ID: 9166574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal tolerance of gadolinium-DOTA and gadolinium-DTPA in rats.
    Brillet G; Dubois M; Beaufils H; Bourbouze R; Deray G
    Invest Radiol; 1994 Mar; 29(3):352-4. PubMed ID: 8175311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
    Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
    Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions.
    Russell EJ; Schaible TF; Dillon W; Drayer B; LiPuma J; Mancuso A; Maravilla K; Goldstein HA
    AJR Am J Roentgenol; 1989 Apr; 152(4):813-23. PubMed ID: 2646872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inverse correlation between T1 relaxation times before and after administration of contrast media in malignant brain tumors.
    Niemi P; Aronen HJ; Kwong KK; Gazit IE; Pardo FS; Rosen BR
    Acad Radiol; 1996 Aug; 3 Suppl 2():S286-8. PubMed ID: 8796582
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of plain and Gd-DTPA-enhanced MR-imaging in children.
    Baierl P; Mühlsteffen A; Haustein J; Bauer WM; Förster C; Fendel H; Niendorf HP
    Pediatr Radiol; 1990; 20(7):515-9. PubMed ID: 2216584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of contrast media for magnetic resonance imaging.
    Goldstein HA; Wiggins JR; Kashanian F
    Ann N Y Acad Sci; 1992 Mar; 649():322-31. PubMed ID: 1580503
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial.
    Niendorf HP; Haustein J; Louton T; Beck W; Laniado M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134
    [No Abstract]   [Full Text] [Related]  

  • 35. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
    VanWagoner M; O'Toole M; Worah D; Leese PT; Quay SC
    Invest Radiol; 1991 Nov; 26(11):980-6. PubMed ID: 1743922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic role of gadolinium-DTPA in pediatric neuroradiology. A retrospective review of 655 cases.
    Ge HL; Hirsch WL; Wolf GL; Rubin RA; Hackett RK
    Neuroradiology; 1992; 34(2):122-5. PubMed ID: 1603309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-dependency in brain lesion enhancement with gadodiamide injection.
    Akeson P; Nordström CH; Holtås S
    Acta Radiol; 1997 Jan; 38(1):19-24. PubMed ID: 9059396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Artificial contrasting during magnetic resonance tomography].
    Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
    Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
    [No Abstract]   [Full Text] [Related]  

  • 40. Considerations in the choice of contrast media for MR imaging.
    Brasch RC; Bennett HF
    Radiology; 1988 Mar; 166(3):897-9. PubMed ID: 3340795
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.